Penumbra DVT FDA clearance is the news in an announcement dated 20 October 2026: the FDA has cleared the company’s Lightning computer assisted vacuum thrombectomy technology, known as CAVT, for treating deep vein thrombosis. Penumbra says it is the first cleared DVT treatment indication among mechanical thrombectomy devices. The clearance was supported by the BOLT-DVT trial, in which the company reports that 98% of patients had complete or near-complete clot removal, median device time was 18 minutes and 3.1% had major adverse events within 48 hours. These are company-reported findings and may not predict outcomes for every patient.
Penumbra DVT FDA clearance: key takeaways
- The FDA cleared Lightning CAVT for treating deep vein thrombosis, according to Penumbra’s announcement of 20 October 2026.
- In BOLT-DVT, the company reports 98% complete or near-complete clot removal and a median device time of 18 minutes.
- It reports a 3.1% major adverse event rate within 48 hours, a 3.9% re-thrombosis rate at 30 days, and no device-related deaths or serious device-related adverse events.
- The release gives no enrolment number, site count or launch date.
- Results are company-reported and may not predict outcomes for all patients.
What the Penumbra DVT FDA clearance covers
The FDA cleared the treatment of deep vein thrombosis for Penumbra’s Lightning CAVT technology, the company says, and describes it as the first cleared DVT treatment indication among mechanical thrombectomy devices. That claim is the company’s, and the release does not quote the full label wording, so readers should consult the instructions for use for the exact indication. Penumbra is based in Alameda, California.
How Lightning CAVT works
According to the company, the CAVT portfolio uses Lightning Flash technology, which applies pressure- and flow-based aspiration control algorithms to detect clot and blood flow during thrombectomy and delivers high-power aspiration for clot removal. Penumbra says the system is designed for speed, safety and simplicity. In plain terms, thrombectomy means removing a clot from a blood vessel, and vacuum thrombectomy does so by suction through a catheter. The computer assistance, as described, helps the system tell clot from flowing blood so that suction is applied where it is needed.
The BOLT-DVT trial behind the Penumbra DVT FDA clearance
BOLT-DVT is described as a prospective, multicenter investigational device exemption trial in patients with iliofemoral DVT, meaning clots in the large veins of the upper leg and pelvis. The company says it builds on the precedent of the earlier ATTRACT randomised trial using modern technology. The co-principal investigators are Patrick Muck, M.D., of TriHealth in Cincinnati, and Kush R. Desai, M.D., of Northwestern Medicine. The release does not state how many patients were enrolled, how many sites took part or the formal endpoint definitions.
Results reported for the Penumbra DVT FDA clearance
- 98% of patients had complete or near-complete thrombus removal.
- Median device time was 18 minutes.
- The 48-hour major adverse event rate was 3.1%.
- The 30-day re-thrombosis rate was 3.9%.
- No device-related deaths or serious device-related adverse events were observed.
- 30-day patency ranged from 88.8% to 96.3% across treated vessels.
- 84.3% of patients had no post-thrombotic syndrome symptoms at 30 days on the Villalta scale (0 to 4).
- Median leg pain fell from 5 at baseline to 0 immediately after the procedure and at 30 days, and median VEINES-QOL scores rose from 49.3 to 84.2.
Why DVT treatment matters
The release cites an estimated 900,000 U.S. venous thromboembolism cases a year, attributing the figure to the American Lung Association, and notes that DVT clots can travel to the lungs and cause pulmonary embolism. Muck said that anticoagulation primarily prevents clot progression and does little to remove the existing clot, which is the gap mechanical thrombectomy aims to fill. Chief Medical Officer James F. Benenati, M.D., called DVT an underestimated health issue. General background: DVT is a clot in a deep vein, most often in the leg, and doctors choose among medicines and procedures depending on the clot and the patient.
How to read the Penumbra DVT FDA clearance data
This section is our analysis. The reported outcomes are favourable, but they come from a single-arm trial, which has no control group and so cannot show that the device is better than medicines alone or than other procedures. The main measures are procedural, such as clot removal and device time, plus a 30-day follow-up, so they say little about long-term outcomes. The company has not given enrolment numbers or full endpoint definitions in the release. Clinicians will look for the full publication to judge these points.
Availability and safety information
The release gives no commercial launch date. It states that U.S. federal law restricts sale of the devices to physicians or on a physician’s order, and points clinicians to the instructions for use for indications, contraindications, warnings and adverse events. It also notes that the company’s forward-looking statements include risks linked to the pending acquisition of Penumbra by Boston Scientific Corporation, which we have not examined. General regulator information is on the FDA medical devices pages.
What is not disclosed about the Penumbra DVT FDA clearance
- Number of patients and sites in BOLT-DVT.
- Formal endpoint definitions and follow-up beyond 30 days.
- Launch timing and pricing.
- Comparisons with other DVT treatments.
Risks and caveats on Penumbra DVT FDA clearance claims
- All results are company-reported and from a single-arm trial.
- Clearance does not show that the device is superior to alternatives.
- General explanations of DVT and thrombectomy are background.
- This is news reporting, not medical advice.
In our assessment, the Penumbra DVT FDA clearance matters because it is the first thrombectomy indication for DVT that the company says has been cleared, and the strength of the evidence will be judged when full BOLT-DVT results are published and compared with existing care. See also Hēlo Thrombectomy FDA Clearance: Blood Return for PE. More in our medical device coverage, and company background is on the Penumbra website.
What to watch next on Penumbra DVT FDA clearance
- Full BOLT-DVT publication and longer follow-up.
- U.S. launch details and hospital adoption.
- Any update on the pending acquisition of Penumbra.
Frequently asked questions
What did the FDA clear?
Penumbra’s Lightning CAVT technology for treating deep vein thrombosis, per the company.
What did BOLT-DVT find?
The company reports 98% complete or near-complete clot removal, a median device time of 18 minutes and a 3.1% major adverse event rate within 48 hours.
Does this guarantee results for every patient?
No. The results are company-reported and may not predict individual outcomes.
How we reported this: we relied on Penumbra’s announcement of 20 October 2026 and public regulator pages. Our analysis and general background are labelled. Last updated: 20 October 2026. This article is news reporting and not medical advice.